BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37704591)

  • 41. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
    Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
    Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma.
    Bolomsky A; Miettinen JJ; Malyutina A; Besse A; Huber J; Fellinger S; Breid H; Parsons A; Klavins K; Hannich JT; Kubicek S; Caers J; Hübl W; Schreder M; Zojer N; Driessen C; Tang J; Besse L; Heckman CA; Ludwig H
    Blood Adv; 2021 Oct; 5(20):4125-4139. PubMed ID: 34478517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
    Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
    Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
    Pei XY; Dai Y; Grant S
    Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
    Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
    Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
    Booher RN; Hatch H; Dolinski BM; Nguyen T; Harmonay L; Al-Assaad AS; Ayers M; Nebozhyn M; Loboda A; Hirsch HA; Zhang T; Shi B; Merkel CE; Angagaw MH; Wang Y; Long BJ; Lennon XQ; Miselis N; Pucci V; Monahan JW; Lee J; Kondic AG; Im EK; Mauro D; Blanchard R; Gilliland G; Fawell SE; Zawel L; Schuller AG; Strack P
    PLoS One; 2014; 9(10):e108371. PubMed ID: 25289887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance.
    Fitzgerald MC; O'Halloran PJ; Kerrane SA; Ní Chonghaile T; Connolly NMC; Murphy BM
    Cell Death Dis; 2023 Oct; 14(10):705. PubMed ID: 37898609
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma.
    Schneller A; Zojer N; Bolomsky A; Ludwig H
    Haematologica; 2021 Sep; 106(9):2516-2521. PubMed ID: 33910332
    [No Abstract]   [Full Text] [Related]  

  • 50. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas.
    Müller D; Mazzeo P; Koch R; Bösherz MS; Welter S; von Hammerstein-Equord A; Hinterthaner M; Cordes L; Belharazem D; Marx A; Ströbel P; Küffer S
    BMC Med; 2021 Nov; 19(1):300. PubMed ID: 34781947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bcl-x
    Rello-Varona S; Fuentes-Guirado M; López-Alemany R; Contreras-Pérez A; Mulet-Margalef N; García-Monclús S; Tirado OM; García Del Muro X
    Sci Rep; 2019 Mar; 9(1):3816. PubMed ID: 30846724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
    Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway.
    Sadahira K; Sagawa M; Nakazato T; Uchida H; Ikeda Y; Okamoto S; Nakajima H; Kizaki M
    Int J Oncol; 2014 Dec; 45(6):2278-86. PubMed ID: 25231749
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance.
    Alcon C; Manzano-Muñoz A; Prada E; Mora J; Soriano A; Guillén G; Gallego S; Roma J; Samitier J; Villanueva A; Montero J
    Cell Death Dis; 2020 Aug; 11(8):634. PubMed ID: 32801295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
    Besbes S; Pocard M; Mirshahi M; Billard C
    Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.
    Melvold K; Giliberto M; Karlsen L; Ayuda-Durán P; Hanes R; Holien T; Enserink J; Brown JR; Tjønnfjord GE; Taskén K; Skånland SS
    Mol Oncol; 2022 Mar; 16(5):1153-1170. PubMed ID: 34861096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins.
    Senft D; Weber A; Saathoff F; Berking C; Heppt MV; Kammerbauer C; Rothenfusser S; Kellner S; Kurgyis Z; Besch R; Häcker G
    Cell Death Dis; 2015 Nov; 6(11):e1996. PubMed ID: 26610208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.
    Fraser CS; Spetz JKE; Qin X; Presser A; Choiniere J; Li C; Yu S; Blevins F; Hata AN; Miller JW; Bradshaw GA; Kalocsay M; Sanchorawala V; Sarosiek S; Sarosiek KA
    Nat Commun; 2022 Oct; 13(1):5789. PubMed ID: 36184661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.